

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 421(TM) anti-human CD3

RRID:AB_2565848

Type: Antibody

Proper Citation

BioLegend Cat# 317343, RRID:AB_2565848

Antibody Information

URL: http://antibodyregistry.org/AB_2565848

Proper Citation: BioLegend Cat# 317343, RRID:AB_2565848

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2565848

Vendor: BioLegend

Catalog Number: 317343

Alternative Catalog Numbers: 317344

Record Creation Time: 20250820T010213+0000

Record Last Update: 20250820T095142+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. *Immunity*, 59(5), 1201.

Rodrigues LN, et al. (2026) Cancer-associated fibroblast subtypes differentially modulate natural killer cells in cancer. *Cell reports*, 45(6), 117527.

Liao CY, et al. (2025) CD3xHER2 bsAb-Mediated Activation of Resting T-cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFN γ and TNF α . *European journal of immunology*, 55(4), e202451589.

Tang L, et al. (2025) Joint analysis of chromatin accessibility and gene expression in the same single cells reveals cancer-specific regulatory programs. *Cell systems*, 16(5), 101266.

Liu M, et al. (2025) NKp46 recognizes the hyphal form of *Candida albicans* and mediates protective antifungal immunity. *iScience*, 28(10), 113556.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.

Vasudev A, et al. (2025) Coordinated changes in stromal and hematopoietic cells that define the perinatal to juvenile transition in the mouse thymus. *Cell reports*, 44(12), 116677.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8 $^{+}$ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. *Cancer cell*.

Liao CY, et al. (2024) CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing. *Communications biology*, 7(1), 983.

Ingels J, et al. (2024) Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. *Cell reports. Medicine*, 5(5), 101516.

Tieu V, et al. (2024) A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. *Cell*, 187(5), 1278.

Jin Z, et al. (2024) GABA-mediated inhibition of human CD4+ T cell functions is enhanced by insulin but impaired by high glucose levels. *EBioMedicine*, 105, 105217.

Plum T, et al. (2020) Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation. *Immunity*, 52(2), 404.

Di Genua C, et al. (2020) C/EBP β and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor. *Cancer cell*, 37(5), 690.

Qiu J, et al. (2020) Retinoic Acid Promotes Endothelial Cell Cycle Early G1 State to Enable Human Hemogenic Endothelial Cell Specification. *Cell reports*, 33(9), 108465.

Walker-Sperling VE, et al. (2017) Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. *EBioMedicine*, 16, 141.